BPC-157 took the headlines. Four other compounds were voted on, one was rejected, and the indications the FDA was actually evaluating had almost nothing to do with how any of these peptides are marketed. Here is the part of the meeting that got skipped.
The complete two-day scorecard
| Compound | Day | Vote | Outcome |
|---|---|---|---|
| BPC-157 | Jul 23 | 8–6–1 | Recommended |
| KPV | Jul 23 | 8–6–1 | Recommended |
| TB-500 | Jul 23 | 8–6–1 | Recommended |
| MOTS-c | Jul 23 | 7–5–2 | Recommended |
| Semax | Jul 24 | 8–5–1 | Recommended |
| Epitalon | Jul 24 | 7–5–1 | Recommended |
| Emideltide (DSIP) | Jul 24 | 6–7–1 | Rejected |
MOTS-c: the narrowest yes
MOTS-c passed 7–5 with two abstentions, the tightest Day 1 margin. It is also the vote where the bloc pattern broke — one of the newly seated appointees abstained rather than voting with the group.
The framing gap is instructive. In the biohacking market MOTS-c is sold as a mitochondrial-derived exercise mimetic: endurance, metabolic flexibility, training output. The FDA evaluated it against obesity and osteoporosis. Those are not the same conversation, and the committee was voting on the second one.
The most consistent finding in the MOTS-c literature is that hard training is itself a powerful upregulator of the pathway. If you are training seriously, you are already pulling the lever the compound is marketed as pulling. That does not make it uninteresting; it makes the marginal case much harder to argue than the marketing suggests.
Semax: cleared, on the widest margin of Day 2
Semax passed 8–5 with one abstention. The FDA evaluated it for cerebral ischemia, migraine, and trigeminal neuralgia — the indications behind its Russian clinical history. The Western wellness market buys it for focus and cognitive output, an application with limited English-language clinical data behind it.
Epitalon: longevity meets the four-factor test
Epitalon cleared 7–5 with one abstention. It is the compound on the docket with the widest gap between claim and evidence: a tetrapeptide with a telomerase and pineal-regulation story attached to it, and a human data set that is thin and largely historical. That it cleared at all says more about the committee’s posture than about the compound.
DSIP: the one that failed
Emideltide, the INN under which DSIP appeared on the FDA docket, was rejected 6–7 with one abstention. It was the only compound on which the committee agreed with FDA staff.
The evaluated indications were opioid withdrawal, chronic insomnia, and narcolepsy. The mechanism is biologically plausible; the human randomized data is thin even by the standards of this docket. A panel that voted against its own agency’s reviewers six consecutive times still could not get there on this one, which is a reasonable signal about where the floor sits.
The rejection does not make DSIP more or less available than it was — it was never legally compoundable and still is not. What it does is remove the near-term prospect of a pharmacy pathway. For recovery-driven sleep quality, the unglamorous levers (consistent timing, temperature, light exposure, alcohol elimination, training load management) still have more evidence behind them than anything on this docket.
What comes next
A second PCAC session is expected around February 2027 covering additional peptide nominations, reportedly including GHK-Cu for non-injectable routes. Between now and then, the FDA decides whether to open rulemaking on any of the six recommended compounds. It is not required to.
Research suppliers for the compounds discussed
Frequently Asked
Emideltide, better known as DSIP or delta sleep-inducing peptide. It failed 6–7 with one abstention — the committee’s only rejection across two days, and the only compound on which the panel agreed with FDA staff.
Seven in favor, five opposed, two abstentions. It was the narrowest of the Day 1 approvals and the first vote where the bloc of new appointees did not move together.
Semax cleared 8–5 with one abstention. Epitalon cleared 7–5 with one abstention. Emideltide was rejected 6–7 with one abstention.
Not the wellness uses these compounds are marketed for. MOTS-c was evaluated in the context of obesity and osteoporosis, Semax for cerebral ischemia, migraine, and trigeminal neuralgia, and DSIP for opioid withdrawal, chronic insomnia, and narcolepsy. The gap between the docket indications and the marketing is worth noticing.
No. All six favorable votes are recommendations that begin a rulemaking process. None of them confers compounding authority today.